Associated Papers
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N et al.
Lung Cancer (amsterdam, Netherlands), 2007
Select a paper to view details